MHK
50
2
VZ
39
2
C
85
3
GWW
65
3
ETN
61
2
STT
67
2
ROST
70
2
UA
38
3
FIS
73
11
PNW
57
2
VMC
59
2
DIS
72
2
FSLR
60
-10
TROW
61
2
PX
55
2
O
35
4
MU
79
3
CPB
37
2
COST
53
5
TGT
52
2
MHK
50
2
VZ
39
2
C
85
3
GWW
65
3
ETN
61
2
STT
67
2
ROST
70
2
UA
38
3
FIS
73
11
PNW
57
2
VMC
59
2
DIS
72
2
FSLR
60
-10
TROW
61
2
PX
55
2
O
35
4
MU
79
3
CPB
37
2
COST
53
5
TGT
52
2
Financhill
Back

Ligand Pharmaceuticals, Inc. 10K Form

Buy
57

LGND
Ligand Pharmaceuticals, Inc.

Last Price:
$197.40
Seasonality Move:
6.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-08 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly
2023-11-09 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly
2023-08-09 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly
2023-05-08 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly
2022-11-08 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly
2022-08-09 10Q LGND/Ligand Pharmaceuticals, Inc. Quarterly

Receive LGND News And Ratings

See the #1 stock for the next 7 days that we like better than LGND

LGND Financial Statistics

Sales & Book Value

Annual Sales: $167.1M
Cash Flow: $4.8M
Price / Cash Flow: 189.9
Annual Sales: $48.34
Price / Book: 4.08

Profitability

EPS (TTM): 2.07770
Net Income (TTM): $48.6M
Gross Margin: $120.8M
Return on Equity: 5.72%
Return on Assets: 4.65%

Ligand Pharmaceuticals, Inc. Earnings Forecast

Key Ligand Pharmaceuticals, Inc. Financial Ratios

  • The Gross Profit Margin over the past 33 years for LGND is 72.28%.
  • The Selling, General & Administrative Expenses for LGND have been equal to 47.06% of Gross Profit Margin.
  • The Research & Development expenses have been 12.82% of Revenue.
  • The Net Earning history of LGND is -2.41% of Total Revenues.
  • Per Share Earnings over the last 33 years have been positive in 18 years.

Ligand Pharmaceuticals, Inc. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: LGND
CUSIP: 53220K
Website: ligand.com

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 24.69
Quick Ratio: 23.64

Price-to-Earnings

Trailing P/E Ratio: 39.38
Forward P/E Ratio: 23.43

LGND Technical Analysis vs Fundamental Analysis

Buy
57
Ligand Pharmaceuticals, Inc. (LGND) is a Buy

Is Ligand Pharmaceuticals, Inc. a Buy or a Sell?